

**Caffeine citrate**

## Section

Medicines administered to the neonate [c]  
 Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)  
 Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)

## Indications

Apnoea of newborn

**Carbetocin**

## Section

Uterotonics  
 Parenteral > General injections > IV: 100 µg per mL (heat stable)

## Indications

Postpartum haemorrhage

**Chlorhexidine**

## Section

Medicines administered to the neonate [c]  
 Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)  
 Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)

## Indications

Omphalitis of newborn

**Clomifene**

## Section

Ovulation inducers  
 Oral > Solid: 50 mg (citrate)

## Indications

Female infertility without specification whether primary or secondary

**Condoms**

## Section

Barrier methods  
 -

## Indications

Contact with health services for contraceptive management

**Copper-containing intrauterine device**

## Section

Intrauterine devices  
 -

## Indications

Contact with health services for insertion of contraceptive device

## Dexamethasone

### Section

Other medicines administered to the mother  
Parenteral > General injections > unspecified: 4 mg per mL  
(dexamethasone phosphate (as sodium))

### Indications

Respiratory distress syndrome of the newborn, altered by maternal corticosteroid therapy

## Diaphragms

### Section

Barrier methods  
-

### Indications

Contact with health services for contraceptive management

## Ergometrine

### Section

Uterotonics  
Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule  
(hydrogen maleate)

### Indications

Postpartum haemorrhage

## Estradiol cypionate + medroxyprogesterone acetate

### Section

Injectable hormonal contraceptives  
Parenteral > General injections > IM: 5 mg + 25 mg

### Indications

Contact with health services for reasons associated with reproduction

## Ethinylestradiol + etonogestrel

### Section

Intravaginal contraceptives  
Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg

### Indications

Contact with health services for contraceptive management

## Ethinylestradiol + levonorgestrel

### Section

Oral hormonal contraceptives  
Oral > Solid: 50 µg + 250 µg [4]  
Oral > Solid: 30 µg + 150 µg

### Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

## Ethinylestradiol + norethisterone

### Section

Oral hormonal contraceptives

Oral > Solid: 35 µg + 1 mg

### Indications

Contact with health services for contraceptive management

## Etonogestrel-releasing implant

### Section

Implantable contraceptives

Implant > Subdermal: 68 mg single rod

### Indications

Contact with health services for insertion of contraceptive device

## Ibuprofen

### Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 5 mg per mL

### Indications

Patent arterial duct

## Indometacin

### Section

Medicines administered to the neonate [c]

### Indications

Therapeutic equivalent to ibuprofen for

Patent arterial duct

## Letrozole

### Section

Ovulation inducers

Oral > Solid > dosage form: 2.5 mg

### Indications

Female infertility without specification whether primary or secondary

## Levonorgestrel

### Section

Oral hormonal contraceptives

Oral > Solid: 750 µg [2]; 1.5 mg [1]

Oral > Solid: 30 µg

Intrauterine devices

Intrauterine system with reservoir containing 52 mg of levonorgestrel.

### Indications

Contact with health services for postcoital contraception

Contact with health services for contraceptive management

Contact with health services for insertion of contraceptive device

## Levonorgestrel-releasing implant

### Section

Implantable contraceptives  
Implant > Subdermal: 75 mg per rod (two-rods)

### Indications

Contact with health services for insertion of contraceptive device

## Medroxyprogesterone acetate

### Section

Injectable hormonal contraceptives  
Parenteral > General injections > IM: 150 mg per mL in 1 mL vial  
Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system

### Indications

Contact with health services for reasons associated with reproduction

## Methylergometrine

### Section

Uterotonics

### Indications

Therapeutic equivalent to ergometrine for

Postpartum haemorrhage

## Mifepristone - misoprostol

### Section

Uterotonics  
Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package

### Indications

Induced abortion

Unspecified time of fetal death, cause not specified

## Misoprostol

### Section

Uterotonics  
Oral > Solid: 200 µg  
Local > Vaginal > tablet: 25 µg

### Indications

Spontaneous abortion, incomplete, without complication

Unspecified obstetric condition

Postpartum haemorrhage

## Multiple micronutrient supplement

### Section

Other medicines administered to the mother

Tablet containing:

Vit A: 800 mcg retinol activity equivalent

Vit C: 70 mg

Vit D: 5 mcg (200 IU)

Vit E: 10 mg alpha tocopherol equivalent

Vit B1: 1.4 mg

Vit B2: 1.4 mg

Vit B3: 18 mg niacin equivalent

Vit B6: 1.9 mg

Folic acid: 400 mcg

Vit B12: 2.6 mcg

Iron: 30 mg

Iodine: 150 mcg

Zinc: 15 mg

Selenium: 65 mcg

Copper: 2 mg

### Indications

Maternal care for other specified conditions predominantly related to pregnancy

## Nifedipine

### Section

Antioxytocs (tocolytics)

Oral > Solid: 10 mg (immediate-release)

### Indications

Preterm labour without delivery

## Norethisterone

### Section

Oral hormonal contraceptives

Oral > Solid: 350 µg

### Indications

Contact with health services for contraceptive management

## Norethisterone enantate

### Section

Injectable hormonal contraceptives

Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution

### Indications

Contact with health services for reasons associated with reproduction

## Oxytocin

### Section

Uterotonics

Parenteral > General injections > unspecified: 10 IU per mL

### Indications

Postpartum haemorrhage

## Progesterone vaginal ring

### Section

Intravaginal contraceptives

Local > Vaginal > vaginal ring: 2.074 g micronized progesterone

### Indications

Contact with health services for contraceptive management

## Prostaglandin E1

### Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 0.5 mg per mL in alcohol

### Indications

Other specified congenital anomaly of great arteries including arterial duct

## Prostaglandin E2

### Section

Medicines administered to the neonate [c]

Parenteral > General injections > IV: 1 mg per mL

### Indications

Therapeutic equivalent to prostaglandin E1 for

Other specified congenital anomaly of great arteries including arterial duct

Other specified congenital anomaly of great arteries including arterial duct

## Surfactant

### Section

Medicines administered to the neonate [c]

Respiratory > Suspension: 80 mg per mL for intratracheal instillation; 25 mg per mL for intratracheal instillation

### Indications

Respiratory distress syndrome of newborn

## Tranexamic acid

### Section

Other medicines administered to the mother

Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule

### Indications

Postpartum haemorrhage

## Ulipristal

### Section

Oral hormonal contraceptives

Oral > Solid: 30 mg tablet (ulipristal acetate)

### Indications

Contact with health services for postcoital contraception